Lilly to Establish USD 5 Billion API Manufacturing Facility in Virginia
The new site in Virginia marks the first of four new US manufacturing sites that Lilly plans to announce this year.
Eli Lilly And Company | 17/09/2025 | By Dineshwori
Alchemab Launches First-in-Human Trial of ATLX-1282, Secures 32 Million USD Financing Boost
Alchemab Therapeutics, a biopharmaceutical company that develops naturally occurring therapeutic antibodies from resilient individuals, has announced the initiation of its first-in-human phase 1 study of ATLX-1282.
Eli Lilly And Company | 10/09/2025 | By Darshana
Lilly Completes Acquisition of Verve Therapeutics
Eli Lilly and Company has completed its acquisition of Verve Therapeutics, a Boston-based clinical-stage firm developing genetic medicines for cardiovascular disease.
Eli Lilly And Company | 26/07/2025 | By Mrinmoy Dey | 121
Juvena Therapeutics & Eli Lilly and Company ink research collaboration focused on muscle health
As part of the collaboration, Juvena will leverage JuvNET, the world’s first, fully integrated, AI-enabled screening platform for mapping the therapeutic potential of stem cell-secreted proteins, developed by Juvena.
Eli Lilly And Company | 15/06/2025 | By Darshana
Nimbus Therapeutics Hits Preclinical Research Milestone with Lilly
Throughout their collaboration, Nimbus has leveraged its computational approaches and structure-based drug design capabilities to help overcome these historical obstacles.
Eli Lilly And Company | 26/02/2025 | By Aishwarya | 203
Eli Lilly's Omvoh Shows Long-Term Efficacy in Crohn's Disease: VIVID-2 Study Results Announced
Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation.
Eli Lilly And Company | 07/02/2025 | By Abha | 202
Lilly and EVA Pharma Secure Approval to Distribute Locally Manufactured Insulin in Egypt
Under this agreement, Lilly has been supplying its active pharmaceutical ingredient (API) for insulin to EVA Pharma at a significantly reduced price and providing pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges.
Eli Lilly And Company | 18/12/2024 | By Aishwarya | 442
Lilly to Invest USD 3 Billion to Expand its Manufacturing Facility in Wisconsin
Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this location.
Eli Lilly And Company | 06/12/2024 | By Aishwarya | 122
Lilly Gets FDA Approval for EBGLYSS for Atopic Dermatitis
Eli Lilly and Company has announced that the US Food and Drug Administration (FDA) approved EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis.
Eli Lilly And Company | 17/09/2024 | By Aishwarya | 416
Lilly to Expand its Manufacturing Site in Ireland with USD 1.8 Billion Investment
The company also unveiled its new USD 800 million facility expansion in Kinsale, Ireland, which began making medicines last year to meet demand for Lilly's latest diabetes and obesity treatments.
Eli Lilly And Company | 13/09/2024 | By Aishwarya | 260
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy